Averin Capital Acquisition Corp. is a SPAC — a blank check company with no operations or revenues — formed to raise capital through an IPO and deploy it into an acquisition of one or more businesses. Averin raised $250M in its IPO by selling 25M units at $10.00 per unit, with proceeds held in trust. Averin has up to 24 months (extendable to 27 months) to complete a business combination; if no deal closes, the SPAC liquidates and public shareholders receive roughly $10.00 per share from the trust. Averin's stated acquisition focus is companies at the intersection of technology and health, including AI, longevity, data-driven care, and deep technology. The sponsor, Averin Capital LLC, paid $25,000 for 7.19M Class B founder shares, which convert into regular equity upon a successful deal — creating highly asymmetric economics for the sponsor relative to public shareholders. The company is led by CEO David Berry, formerly a General Partner at Flagship Pioneering and founder of Valo Health, and is listed on Nasdaq. Public shareholders have downside protection via redemption rights at approximately $10.00 per share, with upside optionality through warrants (1/6 of a warrant per unit, exercisable at $11.50/share).